Vaxxinity Inc. logo

Vaxxinity (VAXX) stock

VAXX · Vaxxinity Inc. · NASDAQ

Website

What is the latest news on VAXX stock?

PRago
Vaxxinity UB-312 Parkinson's Trial Results Published in Nature Medicine

UB-312 is the first Parkinson's candidate to reduce pathology as measured by a seed amplification assay, and suggest clinical improvement on motor experiences of daily living. Data demonstrates target engagement and immunogenicity of the active immunotherapy UB-312 targeting pathological alpha-synuclein. CAPE CANAVERAL, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (OTC:VAXX), a U.S. company pioneering the development of a new class of medicines known as AIMs (active immunotherapy medicines), announced today that Nature Medicine has published groundbreaking exploratory data from the Company's Phase 1 clinical trial of UB-312 in patients with Parkinson's disease (PD). The succes

All VAXX news

Latest news

25 items

Vaxxinity Inc. (VAXX) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for VAXX in the last 30 days. The most recent was published Jun 20, 2024.

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as dementia with Lewy Body and multiple system atrophy; and an anti-tau product candidate for various neurodegenerative conditions, including AD It is also developing UB-313 that targets Calcitonin Gene-Related Peptide to fight migraines; and Anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events, as well as UB-612/UB-612A for Covid-19 prevention. The company has a collaboration with United Biomedical, Inc. for the development of UB-612 in Taiwan. Vaxxinity, Inc. was founded in 2014 and is based in Dallas, Texas.

VAXX FAQ

7 questions
  • What does Vaxxinity Inc. do?
    Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as dementia with Lewy Body and multiple system atrophy; and an anti-tau product candidate for various neurodegenerative conditions, including AD It is also developing...
  • Where does VAXX stock trade?
    Vaxxinity Inc. (VAXX) is listed on NASDAQ.
  • What sector and industry is VAXX in?
    Vaxxinity Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did Vaxxinity Inc. go public?
    Vaxxinity Inc. (VAXX) completed its IPO in 2021.
  • What are analysts saying about VAXX?
    Vaxxinity Inc. has had 5 recent analyst actions on file. The most recent action was from Robert W. Baird: Outperform with a $7.00 price target on 2023-09-08. Recent price targets range from $7.00 to $21.00.
  • What companies are similar to VAXX?
    Notable peers in the same industry include JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), ABT (Abbott Laboratories), LLY (Eli Lilly and Company), NVO (Novo Nordisk A/S). Compare VAXX side-by-side with any of them on Quantisnow.
  • How can I track VAXX on Quantisnow?
    Quantisnow aggregates Vaxxinity Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VAXX to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change